Cytek Biosciences (CTKB) Current Deferred Revenue (2020 - 2026)

Cytek Biosciences' Current Deferred Revenue history runs 7 years deep, the most recent figure standing at $30.0 million for Q1 2026.

• Quarterly Current Deferred Revenue rose 8.4% year-over-year to $30.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $30.0 million (up 8.4% YoY) and the FY2025 annual result came in at $28.5 million, up 11.82% from the prior year.
• Current Deferred Revenue was $30.0 million for Q1 2026 at Cytek Biosciences, up from $28.5 million in the prior quarter.
• Across five years, Current Deferred Revenue topped out at $30.0 million in Q1 2026 and bottomed at $10.0 million in Q1 2022.
• A 5-year average of $22.6 million and a median of $24.0 million in 2024 frame the typical range for Current Deferred Revenue.
• Annual changes were most pronounced in 2022 — Current Deferred Revenue surged 105.49% — and 2024, when it fell 19.13%.
• Cytek Biosciences' Current Deferred Revenue stood at $13.0 million in 2022, then surged by 74.77% to $22.7 million in 2023, then grew by 12.32% to $25.5 million in 2024, then advanced by 11.82% to $28.5 million in 2025, then gained by 5.36% to $30.0 million in 2026.
• Business Quant data shows CTKB's Current Deferred Revenue at $30.0 million in Q1 2026, $28.5 million in Q4 2025, and $28.7 million in Q3 2025.